Targeted Sequencing And Resequencing Market Size, Share & Trends Analysis Report By Technology (NGS, Others), By Workflow, By Application, By Type, By End-use, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global targeted sequencing and resequencing market size was exhibited at USD 6.09 billion in 2022 and is projected to hit around USD 46.76 billion by 2032, growing at a CAGR of 22.61% during the forecast period 2023 to 2032.

Targeted Sequencing And Resequencing Market

Key Pointers:

  • The growth of the overall targeted sequencing and resequencing market is attributed to the increase in the adoption of NGS for various applications including disease diagnosis, drug development, and research applications
  • By sequencing technology, sequencing segment dominated the market owing to the increase in applications of genome sequencing in human genetic research, microbial research, cancer research, and others
  • Clinical application segment held a major share in 2022. Targeted sequencing has broadly applied in clinical research and trials for patient categorization and the development of targeted therapeutics
  • Drug development segment is expected to show significant market share in the coming years. NGS technology can develop multiple levels of genomic data needed for the drug development process from genetic modification, to transcriptome quantification and profiling, and epigenetic modifications, among others
  • By end-use, Hospitals and clinics is expected show a significant market share in the forecast period. This is attributed to the increasing usage of NGS bu clinicians to test several genes for mutations, copy number changes, and fusions
  • North America dominated the targeted sequencing and resequencing market in 2022 due to the presence of key players and favorable government initiatives from the government for increased adoption of NGS technologies

 Targeted Sequencing And Resequencing Market Report Scope

Report Coverage

Details

Market Size in 2023

USD 7.47 Billion

Market Size by 2032

USD 46.76 Billion

Growth Rate from 2023 to 2032

CAGR of 22.61%

Base year

2022

Forecast period

2023 to 2032

Segments covered

Technology, Application, Type, End-use

Regional scope

North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa

Key companies profiled

Agilent Technologies; Illumina, Inc.; F. Hoffmann-La Roche Ltd; GATC Biotech Ag; DNASTAR Inc.; QIAGEN; BGI; Oxford Nanopore Technologies; Thermo Fisher Scientific, Inc.; Perkin Elmer, Inc.; PacBio; RainDance Technologies, Inc.; Bio-Rad Laboratories, Inc.; Integrated DNA Technologies, Inc.; PierianDx; Genomatix GmbH; Macrogen, Inc.

 

Owing to the continuous technological developments in genome sequencers along with broad applications and adoption of NGS technology is expected drive the market growth. Furthermore, the increasing application of NGS in molecular diagnostics and precision medicione is also anticipated to create growth opportunities for market growth.

NGS is expected to witness increasing adoption in various disease conditions and infectious disease treatment, along with Noninvasive Prenatal Testing, transplant medicine, and pharmacogenomics. Targeted gene panels and gene expression profiling through qPCR remain the two most common applications for NGS sequencers in a pathology laboratory. While oncology remains a primary area of NGS use in clinics, pathologists are expected to adopt it in other areas too over the coming years. Such factors are expected to boost market growth in the forecast period.

On the other hand, the introduction of novel products is expected to boost targeted sequencing and resequencing market growth. For instance, in October 2022, the Illumina genomics Forum introduced the NovaSeq X, which can run around 20,000 whole genomes a year on one system. This novel system has 10 billion flow cells. When run at 2×150 base pair reads, it will output 6 TB. Moreover, in December 2021, F. Hoffmann-La Roche AG launched the AVENIO Edge System for simplifying the automation of NGS sample preparation and driving advancements in precision medicine. This novel system is a pre-analytical platform that offers end-to-end, integrated, consistently high-quality outcomes.

Key entities in the targeted sequencing & resequencing market are focusing on collaboration to strengthen their market position. For instance, in March 2021, Illumina collaborated with Geneseeq to commercialize and develop IVD NGS kits in China for cancer care. This novel kit was developed by using Illumina’s NextSeq 550Dx sequencing system, which was approved by China’s NMPA (National Medical Products Administration). Moreover, in March 2021, Hackensack Meridian Health and Genomic Testing Cooperative (GTC) entered into a partnership to establish an oncology-focused RNA and DNA sequencing laboratory in the U.S. This lab—Anthology Diagnostics—will perform NGS of cell-free DNA from liquid biopsy samples and DNA/RNA from tumor samples.

Some of the prominent players in the Targeted Sequencing And Resequencing Market include:

  • Agilent Technologies
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific, Inc.
  • DNASTAR Inc.
  • PacBio
  • Bio-Rad Laboratories, Inc.
  • Integrated DNA Technologies, Inc.
  • Perkin Elmer, Inc.
  • RainDance Technologies, Inc.
  • PierianDx
  • BGI
  • Genomatix GmbH
  • Macrogen, Inc.
  • GATC Biotech Ag
  • Oxford Nanopore Technologies
  • QIAGEN
  • Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Targeted Sequencing And Resequencing market.

By Technology 

  • Sequencing
  • Re-sequencing
    • Electrophoresis-based resequencing
    • NGS
    • Array-based resequencing

By Application 

  • Clinical application
  • Plant and animal sciences
  • Drug development
  • Others

By Type 

  • DNA-based targeted sequencing
  • RNA-based targeted sequencing

By End-use 

  • Hospitals & clinics
  • Academic research
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global targeted sequencing and resequencing market size was exhibited at USD 6.09 billion in 2022 and is projected to hit around USD 46.76 billion by 2032

The global targeted sequencing and resequencing market is expected to grow at a compound annual growth rate of 22.61% from 2023 to 2032

Some key players operating in the targeted sequencing and resequencing market include Agilent Technologies; Illumina, Inc.; F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific, Inc.; DNASTAR Inc.; PacBio; Bio-Rad Laboratories, Inc.; Integrated DNA Technologies, Inc.; Perkin Elmer, Inc.; RainDance Technologies, Inc.; PierianDx; BGI; Genomatix GmbH; Macrogen, Inc.; GATC Biotech Ag; Oxford Nanopore Technologies; and QIAGEN

Key factors that are driving the market growth include increasing research and development activities, increasing number of product launches, decreasing cost of sequencing, and technological advancements.

Chapter 1. Methodology and Scope
                   1.1. Information Procurement
                   1.2. Information or Data Analysis
                   1.3. Market Scope & Segment Definition
                   1.4. Market Model
                       1.4.1. Market Study, By Company Market Share
                       1.4.2. Regional Analysis
Chapter 2. Executive Summary
                   2.1. Market Snapshot
                   2.2. Segment Snapshot
                   2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
                   3.1. Market Segmentation and Scope
                   3.2. Market Lineage Outlook
                       3.2.1. Parent Market Outlook
                       3.2.2. Related/Ancillary Market Outlook
                   3.3. Market Trends and Outlook
                   3.4. Market Dynamics
                       3.4.1. Cost-saving advantages pertaining to the adoption of targeted sequencing approach as well as reducing sequencing cost
                       3.4.2. Advantages associated with targeted gene panels and amplicon sequencing
                       3.4.3. Technological advancements in sequencing technology and related ancillary protocols
                       3.4.4. Advancements to perform sequencing in less time
                       3.4.5. Introduction of digital next-generation sequencing technology
                       3.4.6. Rising number of targeted sequencing-based research projects and consequent popularity growth of genomic medicine
                   3.5. Market Restraint Analysis
                       3.5.1. Challenges in handling & managing sequencing technologies in developing countries
                       3.5.2. High cost associated with installation & maintenance of sequencing facility
                       3.5.3. Lack of skilled & trained personnel
                       3.5.4. Limited access to tools for genomic data manipulation and analysis
                   3.6. Penetration and Growth Prospect Mapping 2023
                   3.7. Business Environment Analysis
                       3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
                       3.7.2. Porter’s Five Forces Analysis
                   3.8. COVID-19 Impact Analysis
Chapter 4. Technology Business Analysis
                   4.1. Targeted Sequencing and Resequencing Market: Technology Movement Analysis
                   4.2. Sequencing
                       4.2.1. Sequencing Market, 2020 - 2032
                   4.3. Re sequencing
                       4.3.1. Re sequencing market, 2020 - 2032
                           4.3.1.1. Electrophoresis-based sequencing
                               4.3.1.1.1. Electrophoresis-based sequencing market, 2020 - 2032
                           4.3.1.2. NGS
                               4.3.1.2.1. NGS market, 2020 - 2032
                           4.3.1.3. Array-based sequencing
                               4.3.1.3.1. Array-based sequencing market, 2020 - 2032
Chapter 5. Application Business Analysis
                   5.1. Targeted Sequencing and Resequencing Market: Application Movement Analysis
                   5.2. Clinical applications
                       5.2.1. Clinical applications market, 2020 - 2032
                   5.3. Plant and animal sciences
                       5.3.1. Plant and animal sciences market, 2020 - 2032
                   5.4. Drug development
                       5.4.1. Drug development market, 2020 - 2032
Chapter 6. Type Business Analysis
                   6.1. Targeted Sequencing and Resequencing Market: Type Movement Analysis
                   6.2. DNA-based targeted sequencing
                       6.2.1. DNA-based targeted sequencing market, 2020 - 2032
                   6.3. RNA-based targeted sequencing
                       6.3.1. RNA-based targeted sequencing market, 2020 - 2032
Chapter 7. End-use Business Analysis
                   7.1. Targeted Sequencing and Resequencing Market: End-use Movement Analysis
                   7.2. Hospitals and clinics
                       7.2.1. Hospitals and clinics market, 2020 - 2032
                   7.3. Academic research
                       7.3.1. Academic research market, 2020 - 2032
                   7.4. Others
                       7.4.1. Others market, 2020 - 2032
Chapter 8. Regional Business Analysis
                   8.1. Targeted Sequencing and Resequencing Market Share By Region, 2023 & 2032
                   8.2. North America
                       8.2.1. SWOT Analysis
                       8.2.2. North America Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.2.3. U.S.
                           8.2.3.1. Key Country Dynamics
                           8.2.3.2. Target Disease Prevalence
                           8.2.3.3. Competitive Scenario
                           8.2.3.4. Regulatory Framework
                           8.2.3.5. Reimbursement Scenario
                           8.2.3.6. U.S. Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.2.4. Canada
                           8.2.4.1. Key Country Dynamics
                           8.2.4.2. Target Disease Prevalence
                           8.2.4.3. Competitive Scenario
                           8.2.4.4. Regulatory Framework
                           8.2.4.5. Reimbursement Scenario
                           8.2.4.6. Canada Targeted Sequencing and Resequencing Market, 2020 - 2032
                   8.3. Europe
                       8.3.1. SWOT Analysis
                       8.3.2. Europe Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.3.3. Germany
                           8.3.3.1. Key Country Dynamics
                           8.3.3.2. Target Disease Prevalence
                           8.3.3.3. Competitive Scenario
                           8.3.3.4. Regulatory Framework
                           8.3.3.5. Reimbursement Scenario
                           8.3.3.6. Germany Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.3.4. U.K.
                           8.3.4.1. Key Country Dynamics
                           8.3.4.2. Target Disease Prevalence
                           8.3.4.3. Competitive Scenario
                           8.3.4.4. Regulatory Framework
                           8.3.4.5. Reimbursement Scenario
                           8.3.4.6. UK Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.3.5. France
                           8.3.5.1. Key Country Dynamics
                           8.3.5.2. Target Disease Prevalence
                           8.3.5.3. Competitive Scenario
                           8.3.5.4. Regulatory Framework
                           8.3.5.5. Reimbursement Scenario
                           8.3.5.6. France Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.3.6. Italy
                           8.3.6.1. Key Country Dynamics
                           8.3.6.2. Target Disease Prevalence
                           8.3.6.3. Competitive Scenario
                           8.3.6.4. Regulatory Framework
                           8.3.6.5. Reimbursement Scenario
                           8.3.6.6. Italy Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.3.7. Spain
                           8.3.7.1. Key Country Dynamics
                           8.3.7.2. Target Disease Prevalence
                           8.3.7.3. Competitive Scenario
                           8.3.7.4. Regulatory Framework
                           8.3.7.5. Reimbursement Scenario
                           8.3.7.6. Spain Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.3.8. Denmark
                           8.3.8.1. Key Country Dynamics
                           8.3.8.2. Target Disease Prevalence
                           8.3.8.3. Competitive Scenario
                           8.3.8.4. Regulatory Framework
                           8.3.8.5. Reimbursement Scenario
                           8.3.8.6. Denmark Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.3.9. Sweden
                           8.3.9.1. Key Country Dynamics
                           8.3.9.2. Target Disease Prevalence
                           8.3.9.3. Competitive Scenario
                           8.3.9.4. Regulatory Framework
                           8.3.9.5. Reimbursement Scenario
                           8.3.9.6. Sweden Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.3.10. Norway
                           8.3.10.1. Key Country Dynamics
                           8.3.10.2. Target Disease Prevalence
                           8.3.10.3. Competitive Scenario
                           8.3.10.4. Regulatory Framework
                           8.3.10.5. Reimbursement Scenario
                           8.3.10.6. Norway Targeted Sequencing and Resequencing Market, 2020 - 2032
                   8.4. Asia Pacific
                       8.4.1. SWOT Analysis
                           8.4.1.1. Asia Pacific Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.4.2. Japan
                           8.4.2.1. Key Country Dynamics
                           8.4.2.2. Target Disease Prevalence
                           8.4.2.3. Competitive Scenario
                           8.4.2.4. Regulatory Framework
                           8.4.2.5. Reimbursement Scenario
                           8.4.2.6. Japan Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.4.3. China
                           8.4.3.1. Key Country Dynamics
                           8.4.3.2. Target Disease Prevalence
                           8.4.3.3. Competitive Scenario
                           8.4.3.4. Regulatory Framework
                           8.4.3.5. Reimbursement Scenario
                           8.4.3.6. China Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.4.4. India
                           8.4.4.1. Key Country Dynamics
                           8.4.4.2. Target Disease Prevalence
                           8.4.4.3. Competitive Scenario
                           8.4.4.4. Regulatory Framework
                           8.4.4.5. Reimbursement Scenario
                           8.4.4.6. India Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.4.5. South Korea
                           8.4.5.1. Key Country Dynamics
                           8.4.5.2. Target Disease Prevalence
                           8.4.5.3. Competitive Scenario
                           8.4.5.4. Regulatory Framework
                           8.4.5.5. Reimbursement Scenario
                           8.4.5.6. South Korea Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.4.6. Australia
                           8.4.6.1. Key Country Dynamics
                           8.4.6.2. Target Disease Prevalence
                           8.4.6.3. Competitive Scenario
                           8.4.6.4. Regulatory Framework
                           8.4.6.5. Reimbursement Scenario
                           8.4.6.6. Australia Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.4.7. Thailand
                           8.4.7.1. Key Country Dynamics
                           8.4.7.2. Target Disease Prevalence
                           8.4.7.3. Competitive Scenario
                           8.4.7.4. Regulatory Framework
                           8.4.7.5. Reimbursement Scenario
                           8.4.7.6. Thailand Targeted Sequencing and Resequencing Market, 2020 - 2032
                   8.5. Latin America
                       8.5.1. SWOT Analysis
                       8.5.2. Latin America Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.5.3. Brazil
                           8.5.3.1. Key Country Dynamics
                           8.5.3.2. Target Disease Prevalence
                           8.5.3.3. Competitive Scenario
                           8.5.3.4. Regulatory Framework
                           8.5.3.5. Reimbursement Scenario
                           8.5.3.6. Brazil Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.5.4. Mexico
                           8.5.4.1. Key Country Dynamics
                           8.5.4.2. Target Disease Prevalence
                           8.5.4.3. Competitive Scenario
                           8.5.4.4. Regulatory Framework
                           8.5.4.5. Reimbursement Scenario
                           8.5.4.6. Mexico Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.5.5. Argentina
                           8.5.5.1. Key Country Dynamics
                           8.5.5.2. Target Disease Prevalence
                           8.5.5.3. Competitive Scenario
                           8.5.5.4. Regulatory Framework
                           8.5.5.5. Reimbursement Scenario
                           8.5.5.6. Argentina Targeted Sequencing and Resequencing Market, 2020 - 2032
                   8.6. MEA
                       8.6.1. SWOT Analysis
                       8.6.2. MEA Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.6.3. South Africa
                           8.6.3.1. Key Country Dynamics
                           8.6.3.2. Target Disease Prevalence
                           8.6.3.3. Competitive Scenario
                           8.6.3.4. Regulatory Framework
                           8.6.3.5. Reimbursement Scenario
                           8.6.3.6. South Africa Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.6.4. Saudi Arabia
                           8.6.4.1. Key Country Dynamics
                           8.6.4.2. Target Disease Prevalence
                           8.6.4.3. Competitive Scenario
                           8.6.4.4. Regulatory Framework
                           8.6.4.5. Reimbursement Scenario
                           8.6.4.6. Saudi Arabia Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.6.5. UAE
                           8.6.5.1. Key Country Dynamics
                           8.6.5.2. Target Disease Prevalence
                           8.6.5.3. Competitive Scenario
                           8.6.5.4. Regulatory Framework
                           8.6.5.5. Reimbursement Scenario
                           8.6.5.6. UAE Targeted Sequencing and Resequencing Market, 2020 - 2032
                       8.6.6. Kuwait
                           8.6.6.1. Key Country Dynamics
                           8.6.6.2. Target Disease Prevalence
                           8.6.6.3. Competitive Scenario
                           8.6.6.4. Regulatory Framework
                           8.6.6.5. Reimbursement Scenario
                           8.6.6.6. Kuwait Targeted Sequencing and Resequencing Market, 2020 - 2032
Chapter 9. Competitive Landscape
                   9.1. Participant’s overview
                   9.2. Financial performance
                   9.3. Participant categorization
                       9.3.1. Market Leaders
                       9.3.2. Targeted Sequencing and Resequencing Market Share Analysis, 2023
                       9.3.3. Company Profiles
                           9.3.3.1. Illumina, Inc.
                           9.3.3.2. F. Hoffmann-La Roche Ltd
                           9.3.3.3. Agilent Technologies
                           9.3.3.4. GATC Biotech Ag
                           9.3.3.5. Oxford Nanopore Technologies
                           9.3.3.6. Thermo Fisher Scientific, Inc.
                           9.3.3.7. DNASTAR Inc.
                           9.3.3.8. QIAGEN
                           9.3.3.9. BGI
                           9.3.3.10. Perkin Elmer, Inc.
                           9.3.3.11. PacBio
                           9.3.3.12. Bio-Rad Laboratories, Inc.
                           9.3.3.13. Integrated DNA Technologies, Inc.
                           9.3.3.14. RainDance Technologies, Inc.
                           9.3.3.15. PierianDx
                           9.3.3.16. Genomatix GmbH
                           9.3.3.17. Macrogen, Inc.
                       9.3.4. Strategy Mapping
                           9.3.4.1. Expansion
                           9.3.4.2. Acquisition
                           9.3.4.3. Collaborations
                           9.3.4.4. Product/Service Launch
                           9.3.4.5. Partnerships
                           9.3.4.6. Others

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert